0HL9 Stock Overview A clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Affimed Historical stock prices Current Share Price US$1.30 52 Week High US$8.90 52 Week Low US$1.15 Beta 2.06 1 Month Change -53.07% 3 Month Change -62.15% 1 Year Change -78.69% 3 Year Change -97.67% 5 Year Change n/a Change since IPO -94.69%
Recent News & Updates
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) Dec 18
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Dec 10
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients Dec 09
Affimed N.V. to Report Q3, 2024 Results on Nov 14, 2024 Nov 06
Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma Nov 05
Affimed N.V. Announces Chief Executive Officer Changes Sep 03 See more updates
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) Dec 18
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Dec 10
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients Dec 09
Affimed N.V. to Report Q3, 2024 Results on Nov 14, 2024 Nov 06
Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma Nov 05
Affimed N.V. Announces Chief Executive Officer Changes Sep 03
Affimed N.V. to Report Q2, 2024 Results on Sep 05, 2024 Aug 29
Affimed N.V. to Report Q1, 2024 Results on Jun 12, 2024 Jun 08 Affimed N.V., Annual General Meeting, Jun 26, 2024
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 May 24
Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 22
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer Jan 09 Affimed N.V. Announces CEO Changes Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)
Affimed N.V. Announces Executive Changes Dec 03 Affimed N.V. Announces Changes to its Board
Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells Nov 04
Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting Nov 03 Affimed Announces Listing Transfer to Nasdaq Capital Markets Oct 05
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma Sep 13
Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability Aug 23
New major risk - Revenue and earnings growth Aug 14
New major risk - Revenue and earnings growth Aug 13
Second quarter 2023 earnings released: €0.20 loss per share (vs €0.13 loss in 2Q 2022) Aug 11
Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index Jun 25
New minor risk - Market cap size Jun 25
Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board Jun 23 Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy May 24
First quarter 2023 earnings released: €0.21 loss per share (vs €0.14 loss in 1Q 2022) May 24
Affimed N.V., Annual General Meeting, Jun 21, 2023 May 23
Affimed N.V. to Report Q1, 2023 Results on May 23, 2023 May 17
Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association May 12
Full year 2022 earnings released: €0.60 loss per share (vs €0.48 loss in FY 2021) Mar 24
Affimed N.V. Provides Regulatory Update for AFM13 Jan 10
Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia Dec 24 Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells
Third quarter 2022 earnings released: €0.11 loss per share (vs €0.14 loss in 3Q 2021) Nov 16
Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022 Nov 05
Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting Nov 04
Now 22% undervalued Sep 15
Second quarter 2022 earnings released: €0.13 loss per share (vs €0.16 loss in 2Q 2021) Aug 12
Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Affimed N.V. Establishes Scientific Advisory Board Jul 01
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) Jun 11
First quarter 2022 earnings released: €0.14 loss per share (vs €0.012 profit in 1Q 2021) Jun 02
Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology May 27 Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022
Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity May 18
Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager Apr 12
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting Apr 11
Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors Apr 09
Full year 2021 earnings released: €0.48 loss per share (vs €0.50 loss in FY 2020) Apr 01
Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing Feb 10
Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL Jan 07
Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13 Dec 11
Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab Dec 10
Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center Nov 24
Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020) Nov 11
Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020) Sep 09
First quarter 2021 earnings released: EPS €0.012 (vs €0.11 loss in 1Q 2020) Jul 04
Affimed N.V. Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of Afm13 in Combination with Natural Killer Cells May 14
New 90-day high: US$7.45 Mar 13
Affimed N.V. Announces Continuation of REDIRECT, a Registration-Directed Study of AFM13 in PTCL, After Positive Preplanned Interim Futility Analysis Mar 11
Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors Feb 04
Affimed N.V. has completed a Follow-on Equity Offering in the amount of $100.000002 million. Jan 14
Affimed Announces Pipeline and Business Update Jan 08 Shareholder Returns 0HL9 GB Biotechs GB Market 7D 9.2% 0.2% 0.8% 1Y -78.7% -26.1% 2.7%
See full shareholder returns
Return vs Industry: 0HL9 underperformed the UK Biotechs industry which returned -26.1% over the past year.
Return vs Market: 0HL9 underperformed the UK Market which returned 2.7% over the past year.
Price Volatility Is 0HL9's price volatile compared to industry and market? 0HL9 volatility 0HL9 Average Weekly Movement 13.5% Biotechs Industry Average Movement 7.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HL9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HL9's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Show more Affimed N.V. Fundamentals Summary How do Affimed's earnings and revenue compare to its market cap? 0HL9 fundamental statistics Market cap US$21.15m Earnings (TTM ) -US$72.95m Revenue (TTM ) US$5.88m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HL9 income statement (TTM ) Revenue €5.64m Cost of Revenue €0 Gross Profit €5.64m Other Expenses €75.61m Earnings -€69.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.27 Gross Margin 100.00% Net Profit Margin -1,241.26% Debt/Equity Ratio 46.9%
How did 0HL9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/28 01:52 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Affimed N.V. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough BMO Capital Markets Equity Research Li Wang Watsek Cantor Fitzgerald & Co. Bradley Canino Credit Suisse
Show 10 more analysts 
